Skip to main content
IRWDIronwood Pharmaceuticals, Inc.Buy Wait7.5·$4.34+4.83%

Ironwood Pharmaceuticals (IRWD) Q2 2026 earnings — TrendMatrix coverage

BEAT+12.7% vs estimateEPS $0.31 vs $0.28 estVerdict Buy (Wait)Strong Buy

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.31
Estimate
$0.28
Surprise
+12.7%
Revenue (period 2026-06-30)
$113.0M
Score at report (before → after)
7.37.0/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Ironwood Pharmaceuticals (IRWD) beat the $0.28 estimate with diluted EPS of $0.31 — a large 12.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (7.3/10) to Strong Buy at 7.0/10 after the report — the engine's score fell despite the beat.

Current read · as of 2026-08-23

Where TrendMatrix's rating stands now

TrendMatrix currently rates IRWD Buy (Wait) at 7.5/10.

2 of the last 4 quarters beat the estimate; this quarter's +12.7% surprise compares with a -26.2% four-quarter average. Next scheduled report: 2026-11-09.

What supports the rating

  • Strong overall score: 7.5/10
  • High-quality business

What argues against it

  • Elevated risk factors
  • R/R 1.4x at spot < 1.5 minimum
  • Reward/Risk 1.4:1 at current price — below 1.5:1 minimum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$4.34
Entry target
$4.07
Price target
$5.18
Stop
$3.53
Upside to target
+19.4%
Reward-to-risk
1.4:1

The stock trades at 5.2× trailing but 2.9× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare context

IRWD at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - Specialty & Generic
Market cap
$708.9M
P/E (fwd)
2.9
P/E (ttm)
5.2
52-week range
$1.01$5.78
Off 52-week high
24.9%
RSI (14)
47
Volume vs avg
0.98×
Score today
7.5/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks IRWD Earnings Q2 2026 earnings